Skip to main content
Premium Trial:

Request an Annual Quote

In Brief This Week: Siemens Healthineers, Exosome Diagnostics, 1Drop Diagnostics, and More

NEW YORK (360Dx) – Siemens Healthineers this week announced that it has installed India’s first fully automated Aptio Automation track at Aspira Pathlab and Diagnostic Limited in Mumbai.

Siemens said that Aptio Automation combines advanced solutions, education, support, and process optimization in one "unique answer" to the challenges faced by any mid-size to high-volume labs.

The firm noted that the new track will enable Aspira to perform all routine hematology, biochemistry, and immunoassay tests with a comprehensive selection of pre- and post-analytical modules that automate sample loading, preparation, and handling to free laboratory staff from time-consuming, low-value tasks.

Siemens said in a statement that it believes the installation will provide a "significant boost to availability of in vitro diagnostic testing services in India."

The American Medical Association issued a new CPT Proprietary Analyses (PLA) code for Exosome Diagnostics' ExoDx Prostate (IntelliScore) test. The new 0005U code becomes effective on May 1 and is specific to Exosome's test. The PLA codes are a new addition to the CPT codes. Exosome said that being assigned the new code is a crucial step to expanding commercialization of its test in the US.

Point-of-care instrument maker 1Drop Diagnostics announced a $140,000 grant from the Consortia for Improving Medicine with Innovation & Technology and the National Institute for Biomedical Imaging and Bioengineering to continue funding the firm's collaboration with Massachusetts General Hospital.

The partners are looking at POC diagnostics for heart disease in primary care settings. Additionally, MGH will provide 1Drop with clinical guidance, help identifying unmet clinical needs, and an environment in which to perform validation studies.

Theradiag reported that its first quarter revenues grew 5 percent year over year to €2.3 million ($2.5 million) from €2.2 million a year ago. In vitro diagnostics revenues were down 15 percent to €1.1 million from €1.3 million a year ago, while revenues associated with the firm's theranostics solution, Lisa Tracker, rose 22 percent to €1.1 million from €903,000 a year ago. International sales came in at €1.2 million, accounting for half of the firm's total revenues, it said.

In Brief This Week is a selection of news items that may be of interest to our readers but had not previously appeared on the 360Dx site.